Form 4: ImmuCell Director Bryan K. Gathagan Acquires 1,000 Shares of Common Stock

ImmuCell Corporation Director Bryan K. Gathagan has acquired 1,000 shares of the company's common stock at a price of $6.32 per share, as reported in a recent SEC Form 4 filing.

Summary

• Bryan K. Gathagan, a Director of ImmuCell Corporation (ICCC), acquired 1,000 shares of the company's common stock.
• The transaction occurred on June 12, 2025.
• The shares were purchased at a price of $6.32 per share.
• Following this transaction, Mr. Gathagan directly beneficially owns 1,000 shares of ImmuCell common stock.
• The acquisition was made pursuant to a Rule 10b5-1 trading plan, indicating a pre-arranged purchase.

Sentiment

Score: 7

Explanation: An insider purchase, particularly by a director and under a Rule 10b5-1 plan, generally indicates positive sentiment from management regarding the company's prospects and valuation.

Positives

• An insider (Director Bryan K. Gathagan) purchased shares, which can signal confidence in the company's future prospects.
• The acquisition was made under a Rule 10b5-1 plan, suggesting a planned, non-discretionary investment by the insider.

Future Outlook

This Form 4 filing reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document is an insider transaction report specific to ImmuCell Corporation and does not provide broader industry context or trends.

Related Party Transactions

• Bryan K. Gathagan, a Director of ImmuCell Corporation, acquired 1,000 shares of the company's common stock at $6.32 per share.

Stakeholder Impact

• Shareholders: The insider purchase may be perceived as a positive signal, potentially increasing investor confidence in the company's future performance.

Key Dates

Keywords

ImmuCell Corporation, ICCC, Form 4, Insider Trading, Stock Purchase, Director, Bryan K. Gathagan, Equity Acquisition, Beneficial Ownership, Rule 10b5-1